1. Yue, Qu, Wang, Zhao, Shen, Yixiong, Liu, Boyang, Guo, Hongbo. 2024. Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11, e2309290. doi:10.1002/advs.202309290. https://pubmed.ncbi.nlm.nih.gov/38477507/
2. Jourdain, Alexis A, Begg, Bridget E, Mick, Eran, Burge, Christopher B, Mootha, Vamsi K. 2021. Loss of LUC7L2 and U1 snRNP subunits shifts energy metabolism from glycolysis to OXPHOS. In Molecular cell, 81, 1905-1919.e12. doi:10.1016/j.molcel.2021.02.033. https://pubmed.ncbi.nlm.nih.gov/33852893/
3. Hosono, Naoko. 2019. Genetic abnormalities and pathophysiology of MDS. In International journal of clinical oncology, 24, 885-892. doi:10.1007/s10147-019-01462-6. https://pubmed.ncbi.nlm.nih.gov/31093808/
4. Li, Chen, Feng, Lu, Luo, Wei-Wei, Li, Mi, Shu, Hong-Bing. 2021. The RNA-binding protein LUC7L2 mediates MITA/STING intron retention to negatively regulate innate antiviral response. In Cell discovery, 7, 46. doi:10.1038/s41421-021-00277-y. https://pubmed.ncbi.nlm.nih.gov/34155193/
5. Shen, Lin, Li, Chao, Chen, Fang, Li, Zhanzhan, Li, Na. 2021. CRISPR/Cas9 genome-wide screening identifies LUC7L2 that promotes radioresistance via autophagy in nasopharyngeal carcinoma cells. In Cell death discovery, 7, 392. doi:10.1038/s41420-021-00783-8. https://pubmed.ncbi.nlm.nih.gov/34907164/
6. Liu, Xinlei, Xie, Sijie, Jiang, Xiaoxue, Li, Shujie, Lu, Dongdong. 2024. LUC7L2 accelerates the growth of liver cancer cells by enhancing DNA damage repair via RRAS. In Cells & development, 180, 203976. doi:10.1016/j.cdev.2024.203976. https://pubmed.ncbi.nlm.nih.gov/39571735/
7. Szelest, Monika, Giannopoulos, Krzysztof. 2024. Biological relevance of alternative splicing in hematologic malignancies. In Molecular medicine (Cambridge, Mass.), 30, 62. doi:10.1186/s10020-024-00839-2. https://pubmed.ncbi.nlm.nih.gov/38760666/
8. Jotte, Matthew R M, McNerney, Megan E. . The significance of CUX1 and chromosome 7 in myeloid malignancies. In Current opinion in hematology, 29, 92-102. doi:10.1097/MOH.0000000000000699. https://pubmed.ncbi.nlm.nih.gov/35084368/